Observed Signal · Sep 17, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 1/5 · Sentiment: Positive

MicroLub Raises $10M to Cut Fat Without Compromising Taste

Executive Signal Summary

MicroLub, a deep tech ingredient solutions company spun out from the University of Leeds, has raised $10 million in a funding round led by Northern Gritstone, with participation from existing investors including NPIF II - PXN Equity Finance. The company's patented protein-based technology enables food manufacturers to reduce fat and calories by up to 75% while maintaining taste and texture, addressing the reformulation challenges driven by regulation and GLP-1 drug adoption. The funding will support international expansion into the US and Asian markets, team growth, and converting customer trials into commercial agreements.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

Funding news for a niche ingredient tech startup, not directly impactful to AdTech; no advertising, marketing, or media relevance.

MARKET SIGNALS

Track Funding Signals & Market Shifts

Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.

  • Verified primary sources
  • Automated briefings
  • Instant watchlist setup

Key Takeaways & Evidence Grounding

  • MicroLub raised $10 million in a funding round led by Northern Gritstone.
  • All existing investors participated, including NPIF II - PXN Equity Finance.
  • The technology can reduce fat and calorie content by up to 75%.
  • MicroLub was founded by Professor Anwesha Sarkar from the University of Leeds.
  • The funding will support expansion into the US and Asian markets.
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: Tech.eu (European Tech & Deals)•Published: Sep 17, 2026
Original Coverage Title: “MicroLub raises $10M to cut fat and calories without compromising taste”

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

FoodTechSep 14, 2026

Ferm Labs Raises €3M for Natural Flavor Platform

Ferm Labs, a Swiss-Italian B2B ingredient startup headquartered in Zug, has raised €3 million in a seed round led by CDP Venture Capital's Green Transition Fund, with participation from Fund F, Redstone (with Euregio+ and Alpine VC), and food company Loacker. Founded in 2025 by Stephanie Lüpold and Mattia Baroni, the company uses genetically unmodified microbes to accelerate fermentation from weeks to hours, transforming agricultural side streams into clean-label flavor systems. Its flagship product Kokumesan, upcycled from whey, targets the industrial cheese market in the US and Europe, offering mature cheese flavor while reducing fat, salt, and production costs—claiming 75% cost-in-use savings. The funds will expand bioprocessing facilities in South Tyrol, grow the European B2B sales team, and increase R&D for new product categories, aiming to redefine natural flavors for industrial production.

Read assessment
FundingOct 16, 2026

Microbiotica lands €42M Series C for microbiome therapy

Microbiotica, a British clinical-stage biopharma company, has announced the first close of a €42 million (£36 million) Series C financing round. The round was led by British Business Bank, with participation from Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, and Seventure Partners, and included all existing Series B investors. The funds will be used to advance MB310, its precision microbiome therapy for ulcerative colitis, into Phase 2 clinical development, following positive Phase 1b results. Microbiotica's platform, spun out of the Wellcome Sanger Institute, identifies bacterial strains linked to favorable clinical outcomes. The company also partners with MSD, Cancer Research UK, and Genentech. This funding round is part of a broader trend of European biotech investments in microbiome and related therapies.

Read assessment
FundingNov 12, 2026

Biomatter Raises $18M for AI Enzyme Design

Biomatter, a Vilnius-based enzyme design company, has raised $18 million (€16.2 million) in an oversubscribed Series A round led by Astanor, with participation from existing investors UVC Partners, Inventure, and Metaplanet. Using an AI-driven platform, the company designs custom enzymes from first principles, reducing development time from months or years to weeks. Biomatter has delivered over 50 custom enzymes to more than 25 enterprise clients, including AstraZeneca, BASF, Sanofi, Thermo Fisher Scientific, and Kirin Holdings. Its enzymes are used in commercial products, such as for mRNA research, developed with Thermo Fisher Scientific. The new funding will support a 2,000-square-metre design-and-testing facility in Vilnius, scheduled to open in 2027, and expand commercial operations in the United States.

Read assessment

WATCHLIST & BRIEFINGS

Receive future signals for Funding in your Watchlist briefing

Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.

  • Regular primary-source checks
  • Structured Watchlist briefings
  • Preserves current context